Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

CompletedOBSERVATIONAL
Enrollment

237

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Chronic Kidney FailureSecondary Hyperparathyroidism
Trial Locations (19)

11526

Site Reference ID/Investigator# 32055, Athens

11528

Site Reference ID/Investigator# 32050, Athens

Site Reference ID/Investigator# 32051, Athens

15562

Site Reference ID/Investigator# 32077, Cholargós

17237

Site Reference ID/Investigator# 32049, Athens

31100

Site Reference ID/Investigator# 32061, Lefkada

32100

Site Reference ID/Investigator# 32062, Livadia

34100

Site Reference ID/Investigator# 32056, Chalcis

35100

Site Reference ID/Investigator# 32060, Lamia

38222

Site Reference ID/Investigator# 32075, Volos

48100

Site Reference ID/Investigator# 32054, Preveza

50200

Site Reference ID/Investigator# 32063, Ptolemaida

60100

Site Reference ID/Investigator# 32076, Katerini

65201

Site Reference ID/Investigator# 32059, Kavala

66100

Site Reference ID/Investigator# 32058, Drama

69100

Site Reference ID/Investigator# 32053, Komotini

73100

Site Reference ID/Investigator# 32057, Chania

Unknown

Site Reference ID/Investigator# 5283, Athens

Site Reference ID/Investigator# 32048, Piraeus

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT01081665 - Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism | Biotech Hunter | Biotech Hunter